A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Patients With Painful Diabetic Peripheral Neuropathy
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2015
At a glance
- Drugs Hepatocyte growth factor gene therapy (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Adverse reactions
- Sponsors ViroMed; VM BioPharma
- 21 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2011 Planned end date changed from Sep 2011 to Apr 2012 as reported by ClinicalTrials.gov.
- 09 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.